<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52027">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02002130</url>
  </required_header>
  <id_info>
    <org_study_id>GABA-GAD</org_study_id>
    <nct_id>NCT02002130</nct_id>
  </id_info>
  <brief_title>The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes</brief_title>
  <acronym>GABA</acronym>
  <official_title>The Use of Glutamic Acid Decarboxylase (GAD)and Gamma-Amino Butyric Acid(GABA)in the Treatment of Type I Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Diamyd Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>NOW Foods</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type I Diabetes is an auto immune disease in which the body's immune system attacks and
      destroys the insulin-producing beta cells of the pancreas. Therefore, children affected by
      this condition present with high blood sugars. This condition affects 1:400/500 persons
      worldwide.Type I Diabetes, previously known as Juvenile Diabetes,usually strikes in
      childhood, adolescence, or young adulthood, but lasts for a lifetime. To date, there has
      been no treatments that can arrest, or reverse the ongoing beta cell destruction. We
      hypothesize that GABA, a naturally occurring substance, has the potential to reduce the
      inflammation and protect the pancreatic beta cells from autoimmune destruction. GAD-alum may
      contribute to the preservation of residual insulin secretion in patients with recent onset,
      Type I Diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Compare the effect of oral GABA or oral GABA/GAD combination administration on pancreatic beta cell function by use of insulin</measure>
    <time_frame>12 months after baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>This will be assessed by  total daily insulin dose in treatment cohorts compared to age matched placebo controls before and after 1 year of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the effect of oral GABA or oral GABA/GAD combination administration on pancreatic beta cell function by peptice secretion</measure>
    <time_frame>12 months after baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>This will be assessed by meal stimulated C-peptide secretion  in treatment cohorts compared to age matched placebo controls before and after 1 year of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of oral GABA or GABA/GAD administration on diabetes autoantibodies GAD-65</measure>
    <time_frame>12 months after baseline</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of oral GABA or GABA/GAD administration on diabetes autoantibodies IA2</measure>
    <time_frame>12 months after baseline</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of oral GABA or GABA/GAD administration on diabetes autoantibodies ICA</measure>
    <time_frame>12 months after baseline</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Type I Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo GABA and Placebo GAD-alum</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo formulation, Xylitol,  for Gamma-Amino Butyric Acid (GABA) capsule-identical in appearance and taste,  but no active medication will be taken with meals.Number of pills based on body surface area.
Placebo GAD-alum(Glutamic Acid Decarboxylase in alum) injection- identical in appearance but no active medication will be received at baseline and 1 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GABA and placebo GAD-alum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive the Active GABA (Gamma-Amino Butyric Acid) capsules. Each capsule 250mg. Dosage will be calculated according to body surface area of the child and divided between the 3 meals/day. Larger dose taken with larger meal.
Patients will receive the GAD-alum( Glutamic Acid Decarboxylase in alum) placebo at baseline and 1 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral GABA and GAD-alum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive Oral GABA(Gamma-Amino Butyric Acid) 250mg capsules. Dosage (# of capsules) based on body surface area and divided between the 3 meals/day.
Patients will receive a primary (at baseline)injection of recombinant human GAD(Glutamic Acid Decarboxylase) in a standard vaccine formulation with alum, and a booster injection of the same at 1 month after baseline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xylitol</intervention_name>
    <arm_group_label>Placebo GABA and Placebo GAD-alum</arm_group_label>
    <other_name>Placebo for Gamma-Amino Butyric Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo GAD-alum</intervention_name>
    <arm_group_label>Placebo GABA and Placebo GAD-alum</arm_group_label>
    <arm_group_label>GABA and placebo GAD-alum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glutamic Acid Decarboxylase in alum formulation</intervention_name>
    <arm_group_label>Oral GABA and GAD-alum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gamma-Aminobutyric Acid</intervention_name>
    <arm_group_label>GABA and placebo GAD-alum</arm_group_label>
    <arm_group_label>Oral GABA and GAD-alum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients positive for any of the 3 measured antibodies (GAD-65, IA2 (Islet Cell
             Antibody 2), ICA Islet Cell Antibody)).

          -  They must meet ADA criteria for diabetes: classic symptoms, plus blood sugar &gt;
             200mg/dL or fasting blood sugar &gt; 126 mg/dL.

          -  Must be enrolled with 4 weeks of diagnosis

          -  Females who are post-menarchal must use 2 forms of contraception if not abstinent.
             The types of contraception deemed acceptable would be oral contraceptives,
             intrauterine devices, and barrier methods.

          -  Signed informed consent form.

        Exclusion Criteria:

          -  Chronic systemic steroid use, including inhaled compounds, or any medication which
             can alter glucose metabolism

          -  Obesity, defined as BMI &gt; 95% or BMI &gt; 27 in adolescents with acanthosis score
             between 1-1.5.

          -  Pregnant and/or breast feeding

          -  History of seizure disorder

          -  Patients on medications that may disturb GABA action, such as Baclofen, Valium,
             Acamprosate, Nurontin, or Lyrica

          -  history of any alcoholism or substance abuse.

          -  Chronic Disease (such as liver, cancer, cystic fibrosis, or renal failure)

          -  Chromosome abnormality (such as Trisomy 21, Turner Syndrome, etc.)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth McCormick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division Director Pediatric Endocrinology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandra Martin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pediatric Endocrinology Fellow</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharon D May, BSN</last_name>
    <phone>205-996-2134</phone>
    <email>smay@peds.uab.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra Martin, MD</last_name>
    <phone>205-638-9107</phone>
    <email>amartin@peds.uab.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sharon D. May, BSN</last_name>
      <phone>205-996-2134</phone>
      <email>smay@peds.uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alexandra Martin, MD</last_name>
      <phone>205-638-9107</phone>
      <email>amartin@peds.uab.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kenneth McCormick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Martin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gail Mick, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ambika Ashraf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008 Oct 30;359(18):1909-20. Epub 2008 Oct 8.</citation>
    <PMID>18843118</PMID>
  </reference>
  <reference>
    <citation>Soltani N, Qiu H, Aleksic M, Glinka Y, Zhao F, Liu R, Li Y, Zhang N, Chakrabarti R, Ng T, Jin T, Zhang H, Lu WY, Feng ZP, Prud'homme GJ, Wang Q. GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11692-7. doi: 10.1073/pnas.1102715108. Epub 2011 Jun 27.</citation>
    <PMID>21709230</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 1, 2014</lastchanged_date>
  <firstreceived_date>November 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Butyric Acid</mesh_term>
    <mesh_term>Gamma-Aminobutyric Acid</mesh_term>
    <mesh_term>Aluminum sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
